Edison Scientific, an AI agent-based biotech discovery company, was tapped by the team behind obesity drug startup Metsera to create new biotechs. The story traces Edison’s origin from FutureHouse, which offered OpenAI/Anthropic-style agents for scientific reasoning and spun out Edison Scientific after pharma demand shifted toward a commercial product. Co-founders Sam Rodriques and Andrew White described how major drugmakers made repeated offers to use FutureHouse’s “agents,” prompting the spinout and late-2025 launch of Edison Scientific with $70 million in venture funding. The company’s premise is to scale scientific discovery by letting AI agents carry out reasoning workflows. For investors and platform operators, the development illustrates how AI agent companies are moving from research prototypes to enterprise delivery models aligned with large pharma’s discovery pipelines and speed expectations.